These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36371469)

  • 1. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson's disease.
    Batzu L; Rota S; Hye A; Heslegrave A; Trivedi D; Gibson LL; Farrell C; Zinzalias P; Rizos A; Zetterberg H; Chaudhuri KR; Aarsland D
    NPJ Parkinsons Dis; 2022 Nov; 8(1):154. PubMed ID: 36371469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.
    Pagonabarraga J; Pérez-González R; Bejr-Kasem H; Marín-Lahoz J; Horta-Barba A; Martinez-Horta S; Aracil-Bolaños I; Sampedro F; Campolongo A; Rivas E; Puig-Davi A; Ruiz-Barrios I; Pérez-Pérez J; Pascual-Sedano B; Kulisevsky J
    Parkinsonism Relat Disord; 2022 Dec; 105():132-138. PubMed ID: 35752549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease.
    Gibson LL; Pollak TA; Heslegrave A; Hye A; Batzu L; Rota S; Trivedi D; Nicholson TR; Ffytche D; Zetterberg H; Chaudhuri KR; Aarsland D
    J Parkinsons Dis; 2022; 12(5):1527-1538. PubMed ID: 35466956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
    Rauchmann BS; Schneider-Axmann T; Perneczky R;
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease.
    Pilotto A; Ashton NJ; Lupini A; Battaglio B; Zatti C; Trasciatti C; Gipponi S; Cottini E; Grossi I; Salvi A; de Petro G; Pizzi M; Canale A; Blennow K; Zetterberg H; Padovani A
    J Neurol; 2024 Dec; 271(12):7537-7546. PubMed ID: 39249107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
    Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
    JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
    Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
    J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease.
    Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W
    J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study.
    Ou R; Liu K; Lin J; Yang T; Xiao Y; Wei Q; Hou Y; Li C; Zhang L; Jiang Z; Zhao B; Chen X; Song W; Wu Y; Shang H
    J Neurol; 2024 Apr; 271(4):1837-1843. PubMed ID: 38063869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA Receptor Antibodies and Neuropsychiatric Symptoms in Parkinson's Disease.
    Gibson LL; Pollak TA; Hart M; Heslegrave A; Hye A; Church AJ; Lakdawala N; Nicholson TR; Batzu L; Rota S; Trivedi D; Zetterberg H; Chaudhuri KR; Aarsland D
    J Neuropsychiatry Clin Neurosci; 2023; 35(3):236-243. PubMed ID: 36710627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
    Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
    Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS
    Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson's Disease.
    Pedersen CC; Ushakova A; Alves G; Tysnes OB; Blennow K; Zetterberg H; Maple-Grødem J; Lange J
    NPJ Parkinsons Dis; 2024 Aug; 10(1):162. PubMed ID: 39164268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson's disease.
    Yang D; Xie H; Wu S; Ying C; Chen Y; Ge Y; Yao R; Li K; Jiang Z; Chen G
    NPJ Parkinsons Dis; 2023 Sep; 9(1):132. PubMed ID: 37699957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
    Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
    J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.